Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.

Gooderham M, Elewski BE, Pariser DM, Sofen H, Mendelsohn AM, Rozzo SJ, Li Q.

J Eur Acad Dermatol Venereol. 2019 Apr 29. doi: 10.1111/jdv.15643. [Epub ahead of print] No abstract available.

PMID:
31033068
2.

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.

Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ.

Br J Dermatol. 2013 Feb;168(2):374-80. doi: 10.1111/j.1365-2133.2012.11214.x. Epub 2012 Dec 13.

PMID:
22880843
3.

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.

Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM.

Br J Dermatol. 2010 Jun;162(6):1349-58. doi: 10.1111/j.1365-2133.2010.09707.x. Epub 2010 Apr 14. Review.

PMID:
20394634
4.

Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus.

Jørgensen TN, Alfaro J, Enriquez HL, Jiang C, Loo WM, Atencio S, Bupp MR, Mailloux CM, Metzger T, Flannery S, Rozzo SJ, Kotzin BL, Rosemblatt M, Bono MR, Erickson LD.

J Immunol. 2010 Jan 15;184(2):775-86. doi: 10.4049/jimmunol.0901322. Epub 2009 Dec 16.

5.

Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model.

Khiong K, Murakami M, Kitabayashi C, Ueda N, Sawa S, Sakamoto A, Kotzin BL, Rozzo SJ, Ishihara K, Verella-Garcia M, Kappler J, Marrack P, Hirano T.

J Clin Invest. 2007 May;117(5):1270-81.

6.

Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice.

Gubbels MR, Jørgensen TN, Metzger TE, Menze K, Steele H, Flannery SA, Rozzo SJ, Kotzin BL.

J Immunol. 2005 Nov 1;175(9):6190-6.

7.

Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus.

Amano H, Amano E, Santiago-Raber ML, Moll T, Martinez-Soria E, Fossati-Jimack L, Iwamoto M, Rozzo SJ, Kotzin BL, Izui S.

Arthritis Rheum. 2005 Sep;52(9):2790-8.

8.

Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis.

Kikuchi S, Fossati-Jimack L, Moll T, Amano H, Amano E, Ida A, Ibnou-Zekri N, Laporte C, Santiago-Raber ML, Rozzo SJ, Kotzin BL, Izui S.

J Immunol. 2005 Jan 15;174(2):1111-7.

9.

A novel locus regulates both retroviral glycoprotein 70 and anti-glycoprotein 70 antibody production in New Zealand mice when crossed with BALB/c.

Rigby RJ, Rozzo SJ, Gill H, Fernandez-Hart T, Morley BJ, Izui S, Kotzin BL, Vyse TJ.

J Immunol. 2004 Apr 15;172(8):5078-85.

10.
11.

Aging-dependent exclusion of antigen-inexperienced cells from the peripheral B cell repertoire.

Johnson SA, Rozzo SJ, Cambier JC.

J Immunol. 2002 May 15;168(10):5014-23.

12.

Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus.

Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, Kotzin BL.

Immunity. 2001 Sep;15(3):435-43.

13.

Enhanced susceptibility to lupus contributed from the nonautoimmune C57BL/10, but not C57BL/6, genome.

Rozzo SJ, Vyse TJ, Menze K, Izui S, Kotzin BL.

J Immunol. 2000 May 15;164(10):5515-21.

14.

MHC-linked control of murine SLE.

Ibnou-Zekri N, Vyse TJ, Rozzo SJ, Iwamoto M, Kobayakawa T, Kotzin BL, Izui S.

Curr Top Microbiol Immunol. 1999;246:275-80; discussion 281. Review. No abstract available.

PMID:
10396066
15.

Control of separate pathogenic autoantibody responses marks MHC gene contributions to murine lupus.

Vyse TJ, Halterman RK, Rozzo SJ, Izui S, Kotzin BL.

Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8098-103.

16.

Analysis of MHC class II genes in the susceptibility to lupus in New Zealand mice.

Rozzo SJ, Vyse TJ, David CS, Palmer E, Izui S, Kotzin BL.

J Immunol. 1999 Mar 1;162(5):2623-30.

17.

Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice.

Vyse TJ, Rozzo SJ, Drake CG, Appel VB, Lemeur M, Izui S, Palmer E, Kotzin BL.

J Immunol. 1998 Mar 15;160(6):2757-66.

18.

Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice.

Vyse TJ, Rozzo SJ, Drake CG, Izui S, Kotzin BL.

J Immunol. 1997 Jun 1;158(11):5566-74.

PMID:
9164982
19.

Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis.

Rozzo SJ, Vyse TJ, Drake CG, Kotzin BL.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15164-8.

20.

Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice.

Vyse TJ, Drake CG, Rozzo SJ, Roper E, Izui S, Kotzin BL.

J Clin Invest. 1996 Oct 15;98(8):1762-72.

21.

Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice.

Drake CG, Rozzo SJ, Vyse TJ, Kotzin BL.

Mamm Genome. 1996 Jun;7(6):466-7. No abstract available.

PMID:
8662234
22.

Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice.

Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin BL.

Immunol Rev. 1995 Apr;144:51-74. Review. No abstract available.

PMID:
7590821
23.

Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner.

Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, Kotzin BL.

J Immunol. 1995 Mar 1;154(5):2441-7.

PMID:
7868910
24.

Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus.

Rozzo SJ, Drake CG, Chiang BL, Gershwin ME, Kotzin BL.

J Immunol. 1994 Aug 1;153(3):1340-51.

PMID:
7913114
25.

Development of the T cell receptor repertoire in lpr mice.

Rozzo SJ, Eisenberg RA, Cohen PL, Kotzin BL.

Semin Immunol. 1994 Feb;6(1):19-26. Review.

PMID:
8167303
26.

Generation and characterization of cloned T helper cell lines for anti-DNA responses in NZB.H-2bm12 mice.

Naiki M, Chiang BL, Cawley D, Ansari A, Rozzo SJ, Kotzin BL, Zlotnik A, Gershwin ME.

J Immunol. 1992 Dec 15;149(12):4109-15.

PMID:
1460294
27.

Purification of transfer factors.

Rozzo SJ, Kirkpatrick CH.

Mol Immunol. 1992 Feb;29(2):167-82.

PMID:
1542296
28.

Murine transfer factor. IV. Studies with genetically regulated immune responses.

Rozzo SJ, Merryman CF, Kirkpatrick CH.

Cell Immunol. 1988 Aug;115(1):130-45.

PMID:
3401928
29.

Human tonsillar IgE biosynthesis in vitro. II. Analysis of T cell regulation with monoclonal antibodies.

Ohta K, Rozzo SJ, Hayward AR, Harbeck RJ, Kirkpatrick CH.

J Allergy Clin Immunol. 1988 Feb;81(2):401-12.

PMID:
2892873
30.

Murine transfer factor. III. Specific interactions between transfer factor and antigen.

Kirkpatrick CH, Rozzo SJ, Mascali JJ.

J Immunol. 1985 Dec;135(6):4027-33.

PMID:
2415595
31.

Murine transfer factor. II. Transfer of delayed hypersensitivity to synthetic antigens.

Kirkpatrick CH, Rozzo SJ, Mascali JJ, Merryman CF.

J Immunol. 1985 Mar;134(3):1723-7.

PMID:
2578518

Supplemental Content

Loading ...
Support Center